Welcome to our dedicated page for Revelation Biosciences SEC filings (Ticker: REVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy disclosures in Revelation Biosciences’ 300-page 10-K can feel like wading through a lab notebook. Clinical trial costs for the Gemini TLR-4 agonist, dilution from new share offerings, and FDA risk factors are buried in dense footnotes. If you have ever searched for “Revelation Biosciences insider trading Form 4 transactions” or wondered how to find the next Gemini milestone in an 8-K, you know the challenge.
Stock Titan solves this complexity. Our platform delivers AI-powered summaries that turn every Revelation Biosciences annual report 10-K simplified into a few digestible paragraphs, flags cash-burn trends in each Revelation Biosciences quarterly earnings report 10-Q filing, and provides Form 4 insider transactions real-time alerts the moment executives act. You’ll also see side-by-side comparisons of trial spending, capital raises, and liquidity ratios—without combing through dozens of exhibits.
Looking for practical answers? Use our search bar to surface:
- Revelation Biosciences 8-K material events explained—read-outs on Gemini-SSI or AKI trial updates.
- Revelation Biosciences proxy statement executive compensation—breakdowns of option grants and performance milestones.
- Revelation Biosciences earnings report filing analysis—AI commentary on quarter-over-quarter R&D variance.
- Understanding Revelation Biosciences SEC documents with AI—step-by-step guides built for biotech investors.
- Revelation Biosciences executive stock transactions Form 4 to gauge insider conviction before pivotal data drops.
All filings are updated from EDGAR in real time, so you never miss a Gemini program headline. Complex biotech disclosures now read like clear, actionable insights.
Revelation Biosciences, Inc. is soliciting shareholder votes at a Special Meeting to approve a proposal limiting conversions under certain warrants issued September 11, 2025, which could trigger Nasdaq’s 20% share issuance cap. The proposal would constrain issuances under those warrants to avoid exceeding the Exchange Cap. On the record date there were 2,339,306 shares outstanding, with each share entitled to one vote. The warrant holders—Sabby Volatility Warrant Master Fund, Ltd., Armistice Capital Master Fund Ltd. and Hudson Bay Master Fund Ltd.—are interested parties but have agreed to vote their shares in the same proportion as non-interested stockholders. The board recommends voting FOR both Proposal 1 (the conversion limitation) and Proposal 2 (adjournment if insufficient proxies). Shareholders may vote by returning the proxy card or attend and vote telephonically; beneficial owners must obtain a broker or nominee proxy to vote.
Revelation Biosciences, Inc. filed a shelf registration to register shares issuable upon exercise of Class I Common Stock Warrants issued under an inducement letter dated September 10, 2025. The Class I Common Stock Warrants are exercisable for five years after stockholder approval at an exercise price of $2.20 per share. The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling stockholders, but it may receive up to approximately $28,743,000 if all warrants are exercised for cash. The company will pay the fees and expenses of registration. The warrants held by three selling stockholders are reported as 4,519,998, 4,025,001, and 4,520,001 warrants respectively and are subject to 4.99% and 9.99% beneficial ownership limits that can prevent exercise if ownership would exceed those thresholds. The prospectus incorporates prior SEC filings listed in the text.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
